Enfortumab vedotin for Named Patient Import

Enfortumab vedotin for Patients in India

Enfortumab vedotin, a newly approved drug by the FDA has its positive role in metastatic urothelial cancer management. The clinical research outcomes suggest its significance in the treatment of recurrent bladder cancer and urothelial cancer. Enfortumab in India has its scope too. Astellas Pharma is credited for its development. Padcev is the registered trade name. Padcev in India is a noted recommendation by the Medical Oncologists.

Padcev or Enfortumab vedotin in India may be prescribed after due consultations with the patient. Its limited access is clearly due to the registration status in India, this drug is not formally registered. This should not completely limit Indian patients from procuring Padcev. Named Patient licensing channels are available to import Enfortumab vedotin.

Enfortumab vedotin in India? We can help.

If you are advised to import Padcev in India, you can take our help to fast track the process. Our team of professionals will help you network with the suppliers in the Europe who can export the drug to India. We have the track record of supporting Indian patients with the necessary documentation and procedures. The suppliers or sources we connect you with are authorized to facilitate Enfortumab import in India.

Email at nhs@noelbiotech.com or call us on + 91 9677010046 / + 91 9929277766.